EAS guidance regarding combining Lipid-modifying therapy
Watch the video and learn on how to integrate recommendations by European Atherosclerosis Society (EAS) Task Force on combining lipid-modifying therapy into routine practice and have positive impact on Atherosclerotic Cardiovascular Disease (ASCVD) trajectory and burden in high- and very-high-risk patients.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-ae/science/images/image-(21).jpg/jcr:content/image%20(21).jpg)
Related articles
MAT-BH-2200016/v2/Jun 2023